Two Different Labs, Two Different Drugs, Same Unexpected Direction

Two separate research teams, at two different universities, have arrived at the same surprising conclusion: drugs built to fight dementia inflammation may also protect the brain during alcohol withdrawal.

What the University of Kentucky Found

Researchers at UK's Sanders-Brown Center on Aging — published in the journal Alcohol — tested an experimental compound called MW150 in cell culture models mimicking alcohol exposure and withdrawal, according to the University of Kentucky's research office.

The drug was originally designed to hit a specific biological target: the p38α MAPK signaling pathway, which drives neuroinflammation in diseases like Alzheimer's. The UK team, led by researchers in Dr. Linda Van Eldik's laboratory, found MW150 significantly reduced select inflammatory markers specifically during withdrawal periods.

Van Eldik is director of the Sanders-Brown Center on Aging and has spent years developing small-molecule drugs targeting brain inflammation. This wasn't a fishing expedition — they had a mechanistic reason to believe it could work.

Caleb Bailey, Ph.D., co-author and researcher in Van Eldik's lab, put it plainly, according to UKNow: "Alcohol use disorder is incredibly difficult to treat because relapse rates remain so high, especially during withdrawal. We wanted to explore whether reducing inflammation in the brain could potentially lessen some of those effects."

MW150 and a related drug called Neflamapimod are already in clinical trials for dementia and other neurodegenerative conditions. That means the safety groundwork has already been laid. If future studies hold up, the path to repurposing these compounds for alcohol treatment is shorter than starting from zero.

What Virginia Commonwealth University Found

Separately, a research team at VCU published findings in Addiction Biology showing that tideglusib — a drug currently in clinical trials for brain disorders including Alzheimer's — showed promising preclinical results in reducing chronic alcohol consumption and binge drinking, according to MedicalXpress.

Dr. Michael F. Miles, M.D., Ph.D., a professor in VCU's Departments of Pharmacology, Toxicology, and Neurology, led that work. Miles told MedicalXpress directly: "There hasn't been a new medication for alcohol use disorder in more than 15 years. It's a huge public health problem."

Only three FDA-approved medications exist for alcohol use disorder — naltrexone, acamprosate, and disulfiram — and all three have serious limitations. People with kidney or liver problems, or those on opioid medications, often can't use them at all.

The Public Health Numbers Are Brutal

About 1 in 10 Americans ages 12 or older meet the clinical criteria for alcohol use disorder, according to VCU researchers cited by MedicalXpress.

Americans are now more than twice as likely to die from alcohol-related illness than they were 20 years ago. Excessive alcohol use is one of the leading causes of preventable death in the United States.

What the Science Is Actually Saying — and What It Isn't

Both studies are preclinical. That means animal models and cell cultures, not human trials. No one should read these headlines and think a new treatment is around the corner.

The biological rationale is strong, though. Alcohol withdrawal triggers neuroinflammation. Neuroinflammation causes brain damage, contributes to relapse, and makes withdrawal symptoms worse — shaking, anxiety, seizures, cognitive impairment. Drugs already proven to hit inflammation pathways in the brain have a logical reason to help.

The research isn't guessing. It's following a mechanism.

What Mainstream Coverage Is Missing

Most outlets treated these as feel-good science briefs. Fox News lumped the VCU study into a health scroll alongside diet tips and fitness hacks. The coverage undersells the story.

The strategic angle: drug repurposing. The fact that MW150 and Neflamapimod are already in human trials for dementia means the FDA regulatory pathway could be significantly faster if animal data continues to hold. That's the entire strategic significance of the UK findings.

Also missing from most coverage: the treatment gap. Fifteen years without a new approved medication for one of America's top killers. That's a regulatory and pharmaceutical failure that deserves scrutiny, not a footnote.

What This Means for Regular People

If you or someone you know is struggling with alcohol use disorder, nothing changes today. These are lab results. Don't self-medicate with unproven compounds.

But the pipeline just got more interesting. Two independent teams are converging on the same biological target. The drugs involved already have safety data from dementia trials. And the disease burden is catastrophic enough that the NIH and FDA should be pushing human trials on this aggressively — not waiting years for bureaucratic momentum to build.

The science is pointing somewhere real. Whether the institutions responsible for moving it forward will treat it with the urgency the death toll demands remains to be seen.